Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-028346
Filing Date
2025-02-27
Accepted
2025-02-27 07:07:01
Documents
91
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K cgem-20241231.htm   iXBRL 10-K 3214644
2 EX-10.8 cgem-ex10_8.htm EX-10.8 23308
3 EX-10.9 cgem-ex10_9.htm EX-10.9 20257
4 EX-10.34 cgem-ex10_34.htm EX-10.34 20879
5 EX-19.1 cgem-ex19_1.htm EX-19.1 103274
6 EX-21.1 cgem-ex21_1.htm EX-21.1 7844
7 EX-23.1 cgem-ex23_1.htm EX-23.1 2951
8 EX-31.1 cgem-ex31_1.htm EX-31.1 15882
9 EX-31.2 cgem-ex31_2.htm EX-31.2 15657
10 EX-32.1 cgem-ex32_1.htm EX-32.1 14623
11 GRAPHIC img68697568_0.jpg GRAPHIC 220586
  Complete submission text file 0000950170-25-028346.txt   13202466

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20241231.xsd EX-101.SCH 1819456
94 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20241231_htm.xml XML 2174311
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39856 | Film No.: 25672958
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)